Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Suzhou Junji Biotechnology

Request full access

Automating biotech to accelerate life science breakthroughs

ChinaFounded 2020Biotech & Life Sciences

About Suzhou Junji Biotechnology

GentleGen is an innovative biotechnology company headquartered in Suzhou, China, focused on advancing life-science research through highly automated, intelligent genetic technology solutions. The company has built a comprehensive, one-stop gene service platform that integrates automation, robotics, and advanced bioengineering to support a wide range of applications, including gene synthesis, oligonucleotide synthesis, Sanger and next-generation sequencing, gene editing, protein expression, and recombinant antibody development. By combining cutting-edge hardware with software-driven workflows, GentleGen enables researchers and biopharmaceutical companies to accelerate discovery, improve experimental reliability, and significantly reduce development timelines. Beyond its core gene services, GentleGen has developed a robust biopharmaceutical safety evaluation system that supports the research and development of nucleic acid drugs, cell and gene therapies, and protein-based therapeutics. This system helps ensure high standards of quality, safety, and compliance from early-stage research through preclinical and clinical development. GentleGen’s solutions are widely adopted by leading research institutions, pharmaceutical companies, and biotechnology enterprises, with its work cited across internationally recognized scientific publications. Driven by a commitment to technological innovation and global health advancement, GentleGen continues to expand its intellectual property portfolio and strengthen strategic partnerships worldwide. Through automation, precision, and scalability, the company aims to reshape how genetic research is conducted—empowering scientists to focus on discovery while GentleGen delivers the infrastructure that makes modern life-science innovation faster, safer, and more efficient.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
50.9/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, Genetics and genomics, Synthetic Biology, Biotech and Pharma, biotech medtech and e-health, DT and LS, science-based
Technology
Artificial Intelligence
Business model
Manufacturing, SaaS
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Dec 2025 $14M $55M Wuhan Optics Valley Industrial Investment · Tianhui Capital · Lianyungang Jinhai Venture Capital · Jinqiao Fund ↗
SEED✓Equity / VC Apr 2024 $2.8M $11M Mingxi Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Suzhou Junji Biotechnology website traffic

Latest recorded traffic for Suzhou Junji Biotechnology is 170 monthly website visits, down 88.7% over the last three months. Suzhou Junji Biotechnology's team grew 9.1% over the past year.

Latest monthly visits170 3-month web change-88.7% 1-year team growth+9.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Suzhou Junji Biotechnology in its local ecosystem

Live from Dealroom

The Suzhou Junji Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Suzhou Wuzhong Biomedical Industrial Park
  • Oriental Fortune
  • Mingxi Capital

Series A4 investors entered at this stage

  • Wuhan Optics Valley Industrial Investment
  • Tianhui Capital
  • Lianyungang Jinhai Venture Capital
  • Jinqiao Fund
Employees 12 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Suzhou Junji Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Suzhou Junji Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.